SSIP and Frontier Space Join Forces to Advance Microgravity-Enabled Life Sciences

Space is increasingly becoming more than a destination. For pharmaceutical, biotechnology and life sciences companies, microgravity is emerging as a unique research environment — one in which biological systems, proteins, cells and materials can behave differently from their counterparts on Earth.

The challenge now is no longer simply demonstrating that scientifically valuable research can be conducted in space. It is turning that capability into repeatable, accessible and commercially relevant industrial processes.

That opportunity is at the heart of a new partnership between the Space Systems Innovation Platform (SSIP) in Switzerland and UK-based Frontier Space Technologies. The collaboration combines two complementary capabilities: Frontier Space's developing orbital biotechnology infrastructure and SSIP's role in connecting industry, research institutions and international technology partners across Switzerland and beyond.

The ambition is clear: to make space-enabled biotechnology easier for terrestrial industry to access, evaluate, validate and ultimately use.

For decades, biological research in space was largely associated with government programmes, astronauts and experiments conducted aboard institutional space stations. That model is changing.

The emergence of autonomous laboratories, commercial launch services, miniaturised scientific hardware and increasingly capable return systems is creating a new infrastructure through which companies can conduct experiments in microgravity and bring data, samples and knowledge back to Earth.

But access to orbit alone will not drive industrial adoption. Companies need a clear scientific rationale, technical feasibility, repeatability, regulatory understanding and, above all, a credible path from an experiment to an industrial outcome. This is precisely where the SSIP–Frontier Space collaboration intends to create value.

Frontier Space is developing SpaceLab, a modular and autonomous platform designed to enable biotechnology and life sciences research in microgravity. Its approach is intended to make orbital experimentation increasingly accessible to organisations that do not traditionally operate within the space sector.

SSIP approaches the opportunity from the opposite direction. Based at Technopark Luzern, the Space Systems Innovation Platform operates as an independent innovation ecosystem connecting industry, academia, research organisations and international technology providers across space, deep tech, microgravity and life sciences.

Only when a credible case exists does microgravity become part of the potential solution. That distinction is central to the partnership.

Switzerland offers an exceptional environment for the development of space-enabled life sciences. Its concentration of pharmaceutical companies, biotechnology organisations, research institutions, precision engineering expertise and advanced manufacturing capabilities creates a strong foundation for translating microgravity research into terrestrial applications.

The collaboration between SSIP and Frontier Space therefore goes beyond simply facilitating access to orbital infrastructure. It is about creating a pathway connecting industry, science and commercialisation:

1. Step 01

   Industrial challenges on Earth
2. Step 02

   Scientific validation
3. Step 03

   Microgravity experimentation
4. Step 04

   Data and sample analysis
5. Step 05

   Technology validation
6. Step 06

   Industrial application
7. Step 07

   Commercialisation

For companies outside the traditional space sector, launch is only one component of that journey. The real value lies in everything that happens before and after it.

The partnership will explore opportunities to connect Swiss and international companies, research institutions and technology organisations with Frontier Space's microgravity capabilities. Potential areas of collaboration include pharmaceutical and biotechnology R&D, protein crystallisation, cellular research, biological manufacturing, advanced life sciences and joint industrial pilot programmes.

Projects can also be evaluated before any orbital campaign is considered — assessing the scientific hypothesis, technical feasibility, commercial potential and possible pathway towards industrialisation. This approach is designed to avoid treating space as an objective in itself. Instead, microgravity becomes another advanced technological capability available to researchers and industry when it can generate measurable value.

"For us, the objective is not to convince companies that they need space. It is to understand their industrial and scientific challenges and determine whether microgravity can genuinely create value. Frontier Space gives us access to a highly relevant technological capability, while SSIP can help build the ecosystem around that capability — from scientific partners and industry to validation and commercial translation."

The success of the collaboration will ultimately not be measured by the number of organisations interested in microgravity. It will be measured by what comes out of it: experiments, validated technologies, industrial pilots, new intellectual property and commercial applications — and potentially new international research and industrial programmes connecting Switzerland with a rapidly developing commercial space infrastructure.

The wider question surrounding microgravity research is gradually evolving from "Can we do this in space?" to "Where can space create enough value to justify doing it?" For Switzerland's sophisticated pharmaceutical, biotechnology and advanced-technology ecosystem, that second question is considerably more important. SSIP and Frontier Space now intend to help answer it.